1. Search Result
Search Result
Results for "

insulin-like

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

1

Screening Libraries

15

Peptides

5

Inhibitory Antibodies

6

Natural
Products

60

Recombinant Proteins

4

Isotope-Labeled Compounds

28

Antibodies

13

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15494
    Picropodophyllin
    25+ Cited Publications

    AXL1717; Picropodophyllotoxin; PPP

    IGF-1R Apoptosis Endocrinology Cancer
    Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin
  • HY-14734
    Anamorelin
    5+ Cited Publications

    RC-1291; ONO-7643

    GHSR Endocrinology Cancer
    Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
    Anamorelin
  • HY-10262
    BMS-536924
    5+ Cited Publications

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity .
    BMS-536924
  • HY-144873

    Insulin Receptor Apoptosis Cancer
    AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 with a good affinity of Kd of 1.4μM. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation .
    AVJ16
  • HY-50866
    NVP-AEW541
    10+ Cited Publications

    AEW541

    IGF-1R Insulin Receptor Autophagy Endocrinology Cancer
    NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 has antitumor activity .
    NVP-AEW541
  • HY-P99294
    Ganitumab
    1 Publications Verification

    AMG 479; Human Anti-IGF1R Recombinant Antibody

    IGF-1R Cancer
    Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
    Ganitumab
  • HY-W010128

    6-Dimethylaminopurine; 6-DMAP

    CDK DNA/RNA Synthesis Apoptosis Cancer
    6-(Dimethylamino) purine (6-Dimethylaminopurine) is a serine threonine protein kinase inhibitor. 6-(Dimethylamino) purine can inhibit prolactin induced expression of lactoprotein genes in rabbit mammary gland cells. 6-(Dimethylamino) purine can affect the maturation of mammalian oocytes. 6-(Dimethylamino) purine can lead to downregulation of genes related to cell proliferation and cell cycle progression, such as proliferating cell nuclear antigen, insulin-like gene 1, and serine protease inhibitor 2 genes, and induce apoptosis in lymphoma cells (apoptosis) .
    6-(Dimethylamino)purine
  • HY-B0025
    Voglibose
    1 Publications Verification

    Glycosidase Metabolic Disease
    Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis .
    Voglibose
  • HY-P2093
    S961
    5+ Cited Publications

    Insulin Receptor Metabolic Disease
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
    S961
  • HY-14734A
    Anamorelin hydrochloride
    5+ Cited Publications

    RC-1291 hydrochloride; ONO-7643 hydrochloride

    GHSR Endocrinology Cancer
    Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia .
    Anamorelin hydrochloride
  • HY-10524
    GSK1904529A
    5+ Cited Publications

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity .
    GSK1904529A
  • HY-P99197

    CP-751871

    IGF-1R Cancer
    Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
    Figitumumab
  • HY-P2093B
    S961 acetate
    5+ Cited Publications

    Insulin Receptor Metabolic Disease
    S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
    S961 acetate
  • HY-108905

    Human IGF-I; FK 780

    IGF-1R Metabolic Disease
    Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
    Mecasermin
  • HY-10199A
    Ibutamoren
    5 Publications Verification

    MK-677 free base; MK-0677 free base

    GHSR Insulin Receptor Neurological Disease Metabolic Disease
    Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .
    Ibutamoren
  • HY-112606

    RXFP Receptor Others
    ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM . ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
    ML-290
  • HY-P1777

    insulin-like Growth Factor I (24-41)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .
    IGF-I (24-41)
  • HY-18785

    IGF-1R Endocrinology Cancer
    Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R.
    Indirubin Derivative E804
  • HY-117483

    iGluR Neurological Disease
    Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC50 value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .
    Gly-Pro-Glu
  • HY-145110

    IGF-1R Cancer
    IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis .
    IGF-1R inhibitor-2
  • HY-110135A
    NBI-31772 hydrate
    3 Publications Verification

    IGF-1R Neurological Disease
    NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects .
    NBI-31772 hydrate
  • HY-15494R

    AXL1717 (Standard); Picropodophyllotoxin (Standard); PPP (Standard)

    IGF-1R Apoptosis Reference Standards Endocrinology Cancer
    Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin (Standard)
  • HY-P99218

    Sch 717454; 19D12

    IGF-1R Cancer
    Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
    Robatumumab
  • HY-135680
    I-OMe-Tyrphostin AG 538
    1 Publications Verification

    I-OMe-AG 538

    IGF-1R Metabolic Disease Cancer
    I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells.?I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50?of 1 μM .
    I-OMe-Tyrphostin AG 538
  • HY-112720
    AGL-2263
    1 Publications Verification

    Insulin Receptor Metabolic Disease Endocrinology
    AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor .
    AGL-2263
  • HY-153485

    ISIS 766720; IONIS-GHR-LRx

    GHR Small Interfering RNA (siRNA) Others
    Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
    Cimdelirsen
  • HY-174655

    mRNA Metabolic Disease
    Human IGF1 mRNA encodes the human insulin like growth factor 1 (IGF1) protein which is involved in mediating growth and development.
    Human IGF1 mRNA
  • HY-114095

    VU0285655-1

    Phospholipase TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology Cancer
    BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research .
    BML-280
  • HY-P2090A

    Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
    Angiopeptin TFA
  • HY-153485A

    ISIS 766720 sodium; IONIS-GHR-LRx sodium

    GHR Small Interfering RNA (siRNA) Others
    Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
    Cimdelirsen sodium
  • HY-13312A

    IGF-1R Insulin Receptor Akt Apoptosis Cancer
    GTx-134 is a dual insulin-like growth factor 1 receptor/insulin receptor (IGF-1R/IR) inhibitor with an IC50 values for IGF-1R and IR of 97 and 187 nM respectively. GTx-134 inhibits the autophosphorylation of IGF-1R and its downstream signaling pathway (Akt), thereby blocking the proliferation and survival signals of tumor cells. GTx-134 has broad-spectrum inhibitory activity against multiple myeloma cell lines and can induce apoptosis in sensitive cells. GTx-134 significantly inhibits tumor growth in mice with MM1.S cell transplantation. GTx-134 works in synergy with existing therapies (such as protease preparations, immunomodulators). GTx-134 can be used in high-risk myeloma research .
    GTx-134
  • HY-P2450

    Antibiotic P168

    Fungal Antibiotic Infection Cancer
    Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies .
    Leucinostatin A
  • HY-P1773

    insulin-like Growth Factor I (30-41)

    Insulin Receptor Metabolic Disease Inflammation/Immunology
    IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
    IGF-I (30-41)
  • HY-177622

    IGF-1R Metabolic Disease
    Cibrigirsen is an antisense oligonucleotide targeted to the insulin-like growth factor I receptor(IGF-1R).
    Cibrigirsen
  • HY-P1773A

    insulin-like Growth Factor I (30-41) TFA

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
    IGF-I (30-41) TFA
  • HY-162506

    IGF-1R Cancer
    IGF-1R inhibitor-3 (Compound C11) is an allosteric inhibitor for insulin-like growth factor receptor 1 kinase (IGF-1R), with an IC50 of 0.2 μM .
    IGF-1R inhibitor-3
  • HY-P1777A

    insulin-like Growth Factor I (24-41) TFA

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .
    IGF-I (24-41) TFA
  • HY-10438

    IGF-1R Cancer
    BMS-577098 is an orally active and ATP-competitive insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 0.016 μM. BMS-577098 shows anti-tumor effect .
    BMS-577098
  • HY-P2093A

    Insulin Receptor Metabolic Disease
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
    S961 TFA
  • HY-P991134

    IGF-1R Inflammation/Immunology
    Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
    Elegrobart
  • HY-P10403

    IGF-1R Inflammation/Immunology Cancer
    IGFBP-3 peptide is a 18-amino acid insulin-like growth factor binding protein-3. IGFBP-3 peptide binds Humanin (HY-P1928) and Hyaluronan (HY-B0633A), blocks the interaction of CD44 and hyaluronan .
    IGFBP-3 peptide
  • HY-118046

    ROCK IGF-1R G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    GSK2163632A is a selective G protein-coupled receptor kinase (GRK) inhibitor that can be used as a probe for studying heart failure and Parkinson's disease. GSK2163632A potently inhibits GRK1 and GRK5, and also inhibits Rho-associated coiled-coil kinase (ROCK) and insulin-like growth factor receptor IGF-1R. GSK2163632A binds to GRK2 in a manner similar to Paroxetine (HY-122272).
    GSK2163632A
  • HY-P11246

    RXFP Receptor Metabolic Disease
    A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
    A13:B7-24-GG
  • HY-174650

    mRNA Metabolic Disease
    Human IGFBP3 mRNA encodes the human insulin like growth factor binding protein 3 (IGFBP3) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP3 can form a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
    Human IGFBP3 mRNA
  • HY-P2090

    Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
    Angiopeptin
  • HY-174649

    mRNA Metabolic Disease
    Human IGFBP4 mRNA encodes the human insulin like growth factor binding protein 4 (IGFBP4) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP4 can bind both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
    Human IGFBP4 mRNA
  • HY-177622A

    IGF-1R Metabolic Disease
    Cibrigirsen sodium is an antisense oligonucleotide targeted to the insulin-like growth factor I receptor(IGF-1R).
    Cibrigirsen sodium
  • HY-174652

    mRNA Metabolic Disease
    Human IGFBP1 mRNA encodes the human insulin like growth factor binding protein 1 (IGFBP1) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP1 is important in cell migration and metabolism.
    Human IGFBP1 mRNA
  • HY-B0025R

    Reference Standards Glycosidase Metabolic Disease
    Voglibose (Standard) is the analytical standard of Voglibose. This product is intended for research and analytical applications. Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis[1].
    Voglibose (Standard)
  • HY-15494S1

    AXL1717-d6; Picropodophyllotoxin-d6; PPP-d6

    Isotope-Labeled Compounds IGF-1R Apoptosis Endocrinology Cancer
    Picropodophyllin-d6 (AXL1717-d6) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: